Cadila Healthcare (CADILAHC), the flagship company of the Zydus Cadila group was incorporated on May 15, 1995 and became public on July 17, 1996. CADILAC was promoted by Ramanbhai B. Patel. The group is engaged in pharmaceuticals (human formulations, veterinary formulations and bulk drugs), diagnostics, herbal products, skin care products and OTC products. Pankaj R. Patel is the chairman and managing director of the company.
The consumer business comprises Sugar Free, a low calorie tabletop sweetener; Everyuth, a range of skin care products; and Nutralite. Cadila Healthcare?s drugs are available as tablets, capsules, liquids, dry syrups, powders and granules, injections and ointments.
The company has already launched 39 new products in the domestic market in 2007. CADILAHC has received approvals from Medicines Control Council of South Africa where the pharmaceutical market is estimated at USD 1 billion. In June 2007, it received approval from the United States Food and Drug Administration to market benzonatate tablets and naproxen tablets in multiple strengths. TGL Enterprises of United States and the company set up a joint venture company, Zydus Noveltech, to develop novel drug delivery based products. On June 25, 2007 CADILAHC acquired 100% stake in Quimica e Farmaceutica Nikkho do Brasil (Nikkho), Brazil for around 26 million dollars. It also acquired Live Healthcare and more recently, Nippon Universal Pharmaceutical. CADILAHC has agreements with Zambon, Italy for manufacturing lyophilised vials and Mayne Pharma, Australia to set up integrated facilities for oncology injectables under a 50:50 JV. Cadila Healthcare has overseas operations in USA, Europe, Japan, Brazil, South Africa, Sri Lanka, Kenya, Czechoslovakia, Romania, Mauritius, Myanmar, Cambodia and the Russian markets. Its registered office is at Ahmedabad, Gujarat.
The consumer business comprises Sugar Free, a low calorie tabletop sweetener; Everyuth, a range of skin care products; and Nutralite. Cadila Healthcare?s drugs are available as tablets, capsules, liquids, dry syrups, powders and granules, injections and ointments.
The company has already launched 39 new products in the domestic market in 2007. CADILAHC has received approvals from Medicines Control Council of South Africa where the pharmaceutical market is estimated at USD 1 billion. In June 2007, it received approval from the United States Food and Drug Administration to market benzonatate tablets and naproxen tablets in multiple strengths. TGL Enterprises of United States and the company set up a joint venture company, Zydus Noveltech, to develop novel drug delivery based products. On June 25, 2007 CADILAHC acquired 100% stake in Quimica e Farmaceutica Nikkho do Brasil (Nikkho), Brazil for around 26 million dollars. It also acquired Live Healthcare and more recently, Nippon Universal Pharmaceutical. CADILAHC has agreements with Zambon, Italy for manufacturing lyophilised vials and Mayne Pharma, Australia to set up integrated facilities for oncology injectables under a 50:50 JV. Cadila Healthcare has overseas operations in USA, Europe, Japan, Brazil, South Africa, Sri Lanka, Kenya, Czechoslovakia, Romania, Mauritius, Myanmar, Cambodia and the Russian markets. Its registered office is at Ahmedabad, Gujarat.
